Suppression of ovarian function by a combined oral contraceptive containing 0.02 mg ethinyl estradiol and 2 mg chlormadinone acetate given in a 24/4-day intake regimen over three cycles

Fertility and Sterility

Volumn 94, Issue 4, 2010, Pages 1195-1201

  Spona, Jürgen ^a   Binder, Natascha ^b   Höschen, Kornelia ^b   Feichtinger, Wilfried ^c  

^a Vitalogic   (Austria)

^b GRÜNENTHAL GMBH   (Germany)

^c Institute for Sterility Treatment   (Austria)

Author keywords

24 4 day intake regimen; chlormadinone acetate; Combined oral contraceptive; low dose ethinylestradiol; oral contraception; ovarian activity; ovarian function

Indexed keywords

CHLORMADINONE ACETATE; CHLORMADINONE ACETATE PLUS ETHINYLESTRADIOL; ETHINYLESTRADIOL; SEX HORMONE; DRUG DOSAGE FORM; ORAL CONTRACEPTIVE AGENT;

ADULT; ARTICLE; CLINICAL TRIAL; DRUG DOSE REGIMEN; DRUG EFFECT; DRUG TOLERABILITY; DRUG TOLERANCE; ENDOMETRIUM; FEMALE; FERTILIZATION; HORMONE BLOOD LEVEL; HUMAN; MAJOR CLINICAL STUDY; MULTIPLE CYCLE TREATMENT; MULTIPLE DRUG DOSE; NORMAL HUMAN; OPEN STUDY; ORAL CONTRACEPTION; OVARY FOLLICLE DEVELOPMENT; OVARY FUNCTION; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; THICKNESS; ADOLESCENT; ALGORITHM; DRUG ADMINISTRATION; DRUG DOSAGE FORM; DRUG EFFECTS; MENSTRUAL CYCLE; OVARY; OVULATION INHIBITION; PHYSIOLOGY; TREATMENT OUTCOME; YOUNG ADULT;

ADOLESCENT; ADULT; ALGORITHMS; CHLORMADINONE ACETATE; CONTRACEPTIVES, ORAL, COMBINED; DOSAGE FORMS; DRUG ADMINISTRATION SCHEDULE; ETHINYL ESTRADIOL; FEMALE; HUMANS; MENSTRUAL CYCLE; OVARY; OVULATION INHIBITION; TREATMENT OUTCOME; YOUNG ADULT;

EID: 77956191467     PISSN: 00150282     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.fertnstert.2009.06.057     Document Type: Article

References (33)

1. Combined oral contraceptives A statement by the committee on safety of drugs Br Med J 2 1970 231 232
2. G. Bettendorf, M. Breckwoldtt, P.J. Keller, H. Kuhl, B. Runnebaum, and W. Braendle Recommendations on oral contraception Der Frauenarzt 38 1997 1058 1062
3. T.N. Jeffcoate R.C.O.G. statement on oral contraceptives Br Med J 2 1970 293
4. H.J. Hoogland, and S.O. Skouby Ultrasound evaluation of ovarian activity under oral contraceptives Contraception 47 1993 583 590
5. J. Spona, N. Binder, K. Höschen, and W. Feichtinger Contraceptive efficacy and safety of a low-dose oral contraceptive, (0.03 mg ethinyl oestradiol and 2 mg chlormadinone acetate) Belara®, over three medication cycles Eur J Contracept Reprod Health Care 13 2008 39 48
6. J. Spona, W. Feichtinger, C. Kindermann, C. Moore, U. Mellinger, and F. Walter Modulation of ovarian function by an oral contraceptive containing 30 micrograms ethinyl estradiol in combination with 2.00 mg dienogest Contraception 56 1997 185 191
7. J. Spona, W. Feichtinger, C. Kindermann, C. Wunsch, and K. Brill Inhibition of ovulation by an oral contraceptive containing 100 micrograms levonorgestrel in combination with 20 micrograms ethinylestradiol Contraception 54 1996 299 304
8. H. Sullivan, H. Furniss, J. Spona, and M. Elstein Effect of 21-day and 24-day oral contraceptive regimens containing gestodene (60 microg) and ethinyl estradiol (15 microg) on ovarian activity Fertil Steril 72 1999 115 120
9. J. Endrikat, M. Cronin, C. Gerlinger, A. Ruebig, W. Schmidt, and B. Dusterberg Open, multicenter comparison of efficacy, cycle control, and tolerability of a 23-day oral contraceptive regimen with 20 microg ethinyl estradiol and 75 microg gestodene and a 21-day regimen with 20 microg ethinyl estradiol and 150 microg desogestrel Contraception 64 2001 201 207
10. J. Spona, M. Elstein, W. Feichtinger, H. Sullivan, F. Ludicke, and U. Muller Shorter pill-free interval in combined oral contraceptives decreases follicular development Contraception 54 1996 71 77
11. C. Klipping, I. Duijkers, D. Trummer, and J. Marr Suppression of ovarian activity with a drospirenone-containing oral contraceptive in a 24/4 regimen Contraception 78 2008 16 25
12. A.J. Rapkin, S.N. Sorger, and S.A. Winer Drospirenone/ethinyl estradiol Drugs Today (Barc) 44 2008 133 145
13. G. Plewig, W.J. Cunliffe, N. Binder, and K. Hoschen Efficacy of an oral contraceptive containing EE 0.03 mg and CMA 2 mg (Belara) in moderate acne resolution: a randomized, double-blind, placebo-controlled phase III trial Contraception 80 2009 25 33
14. G. Schramm, and D. Steffens Contraceptive efficacy and tolerability of chlormadinone acetate 2 mg/ethinylestradiol 0.03 mg (Belara). Results of a post-marketing surveillance study Clin Drug Invest 22 2002 221 231
15. G. Schramm, and D. Steffens A 12-month evaluation of the CMA-containing oral contraceptive Belara: efficacy, tolerability and anti-androgenic properties Contraception 67 2003 305 312
16. U. Winkler, E. Daume, R. Sudik, C. Oberhoff, U. Bier, and C. Hallmann A comparative study of the hemostatic effects of two monophasic oral contraceptives containing 30 mu(g) ethinylestradiol and either 2 mg chlormadinone acetate or 150 mu(g) desogestrel Eur J Contracept Reprod Health Care 4 1999 145 154
17. H.P. Zahradnik, J. Goldberg, and J.O. Andreas Efficacy and safety of the new antiandrogenic oral contraceptive Belara Contraception 57 1998 103 109
18. H.P. Zahradnik, and A. Hanjalic-Beck Efficacy, safety and sustainability of treatment continuation and results of an oral contraceptive containing 30 mcg ethinyl estradiol and 2 mg chlormadinone acetate, in long-term usage (up to 45 cycles) - an open-label, prospective, noncontrolled, office-based Phase III study Contraception 77 2008 337 343
19. C. Brucker, B. Hedon, H.S. The, K. Höschen, N. Binder, and A. Christoph Long-term efficacy and safety of a monophasic combined oral contraceptive containing 0.02 mg ethinylestradiol and 2 mg chlormadinone acetate administered in a 24/4-day regimen Contraception 81 2010 501 509
20. V. Insler, M. Glezerman, and D. Bernstein Diagnosis and treatment of the cervical factor of infertility Reproduccion 5 1981 295 300
21. V. Insler, H. Melmed, I. Eichenbrenner, D. Serr, and B. Lunenfeld The cervical score Int J Gynaecol Obstet 10 1972 223 228
22. I. Worret, W. Arp, H.P. Zahradnik, J.O. Andreas, and N. Binder Acne resolution rates: results of a single-blind, randomized, controlled, parallel phase III trial with EE/CMA (Belara) and EE/LNG (Microgynon) Dermatology 203 2001 38 44
23. J. Endrikat, M. Cronin, C. Gerlinger, A. Ruebig, W. Schmidt, and B. Dusterberg Double-blind, multicenter comparison of efficacy, cycle control, and tolerability of a 23-day versus a 21-day low-dose oral contraceptive regimen containing 20 microg ethinyl estradiol and 75 microg gestodene Contraception 64 2001 99 105
24. F. Ludicke, H. Sullivan, J. Spona, and M. Elstein Dose finding in a low-dose 21-day combined oral contraceptive containing gestodene Contraception 64 2001 243 248
25. A.R. Baerwald, and R.A. Pierson Ovarian follicular development during the use of oral contraception: a review J Obstet Gynaecol Can 26 2004 19 24
26. C. Fitzgerald, W. Feichtinger, J. Spona, M. Elstein, F. Ludicke, and U. Muller A comparison of the effects of two monophasic low dose oral contraceptives on the inhibition of ovulation Adv Contracept 10 1994 5 18
27. S.R. Killick Ovarian follicles during oral contraceptive cycles: their potential for ovulation Fertil Steril 52 1989 580 582
28. B.L. Cohen, and M. Katz Pituitary and ovarian function in women receiving hormonal contraception Contraception 20 1979 475 487
29. I.J. Duijkers, C. Klipping, C.H. Verhoeven, and T.O. Dieben Ovarian function with the contraceptive vaginal ring or an oral contraceptive: a randomized study Hum Reprod 19 2004 2668 2673
30. J. Bitzer Belara - proven benefits in daily practice Eur J Contracept Reprod Health Care 10 Suppl 1 2005 19 25
31. M.P. Curran, and A.J. Wagstaff Ethinylestradiol/chlormadinone acetate Drugs 64 2004 751 760 discussion 61-2
32. H.P. Zahradnik Belara - a reliable oral contraceptive with additional benefits for health and efficacy in dysmenorrhoea Eur J Contracept Reprod Health Care 10 Suppl. 1 2005 12 18
33. J. Endrikat, R. Hite, R. Bannemerschult, C. Gerlinger, and W. Schmidt Multicenter, comparative study of cycle control, efficacy and tolerability of two low-dose oral contraceptives containing 20 microg ethinylestradiol/100 microg levonorgestrel and 20 microg ethinylestradiol/500 microg norethisterone Contraception 64 2001 3 10